 |
|
The Association Between Marijuana Smoking and Lung Cancer
A Systematic Review
Reena Mehra, MD, MS;
Brent A. Moore, PhD;
Kristina Crothers, MD;
Jeanette Tetrault, MD;
David A. Fiellin, MD
Arch Intern Med. 2006;166:1359-1367.
Background The association between marijuana smoking and lung cancer is unclear, and a systematic appraisal of this relationship has yet to be performed. Our objective was to assess the impact of marijuana smoking on the development of premalignant lung changes and lung cancer.
Methods Studies assessing the impact of marijuana smoking on lung premalignant findings and lung cancer were selected from MEDLINE, PSYCHLIT, and EMBASE databases according to the following predefined criteria: English-language studies of persons 18 years or older identified from 1966 to the second week of October 2005 were included if they were research studies (ie, not letters, reviews, editorials, or limited case studies), involved persons who smoked marijuana, and examined premalignant or cancerous changes in the lung.
Results Nineteen studies met selection criteria. Studies that examined lung cancer risk factors or premalignant changes in the lung found an association of marijuana smoking with increased tar exposure, alveolar macrophage tumoricidal dysfunction, increased oxidative stress, and bronchial mucosal histopathologic abnormalities compared with tobacco smokers or nonsmoking controls. Observational studies of subjects with marijuana exposure failed to demonstrate significant associations between marijuana smoking and lung cancer after adjusting for tobacco use. The primary methodologic deficiencies noted include selection bias, small sample size, limited generalizability, overall young participant age precluding sufficient lag time for lung cancer outcome identification, and lack of adjustment for tobacco smoking.
Conclusion Given the prevalence of marijuana smoking and studies predominantly supporting biological plausibility of an association of marijuana smoking with lung cancer on the basis of molecular, cellular, and histopathologic findings, physicians should advise patients regarding potential adverse health outcomes until further rigorous studies are performed that permit definitive conclusions.
Author Affiliations: Departments of Medicine, Case Western Reserve University, Cleveland, Ohio (Dr Mehra), and West Haven Veterans Administration Hospital, West Haven, Conn (Dr Tetrault); and Departments of Medicine (Drs Crothers, Tetrault, and Fiellin) and Psychiatry (Dr Moore), Yale University School of Medicine, New Haven, Conn.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Cannabis: the next villain on the lung cancer battlefield?
Brambilla and Colonna
Eur Respir J 2008;31:227-228.
FULL TEXT
Epidemiology of Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition)
Alberg et al.
Chest 2007;132:29S-55S.
ABSTRACT
| FULL TEXT
|
